Welcome to DailyUpdates Technology Channel: Dedicated to Biologics, Cell & Gene Therapies and Novel Approaches to Vaccines, Drug Delivery, Diagnostics & Drug Development - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 1 more day(s). To receive DailyUpdates by e-mail register here

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Technology Channel: Dedicated to Biologics, Cell & Gene Therapies and Novel Approaches to Vaccines, Drug Delivery, Diagnostics & Drug Development

---

---

• Recommend DailyUpdates
• Other Therapeutic Channels
• UpdatesPlus
• Consultancy
• Modify Subscription
• Past Content
• Submit to DailyUpdates
• Contact

	If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work
Useful Links: Recommend DailyUpdates UpdatesPlus Consultancy Modify your subscription Search past content Submit a paper to DailyUpdates Contact LeadDiscovery	Today's journal articles Long-lasting Complete Regression of Established Mouse Tumors by Counteracting Th2 Inflammation. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study. Potentiated therapeutic angiogenesis by primed human mesenchymal stem cells in a mouse model of hindlimb ischemia. MiR - 125b regulates side population in breast cancer and confers a chemoresistant phenotype. Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know... New Clinical Trials Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022) Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer Previous Journal Entries Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia. Etanercept suppresses arteritis in a murine model of kawasaki disease: a comparative study involving different biological agents. Absence of radiographic progression of hip arthritis during infliximab treatment for ankylosing spondylitis. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Antibody-Functionalized Magnetic Polymersomes: In vivo Targeting and Imaging of Bone Metastases using High Resolution MRI. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs. Safety of biologics approved for treating rheumatoid arthritis: analysis of spontaneous reports of adverse events. A Novel Monoclonal Antibody to Secreted Frizzled-Related Protein 2 Inhibits Tumor Growth. Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2-10-year Etanercept exposure. Elevated level of peripheral CD8(+)CD28 (-) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin. A Phase I Study of Folate Immune Therapy (EC90 Vaccine Administered With GPI-0100 Adjuvant Followed by EC17) in Patients With Renal Cell Carcinoma. Nonviral gene therapy in vivo with PAM-RG4/apoptin as a potential brain tumor therapeutic. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. SiRNA-targeted carboxypeptidase D inhibits hepatocellular carcinoma growth. Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Drug Embedded PVP Coated Magnetic Nanoparticles for Targeted Killing of Breast Cancer Cells. RNAi‑mediated knockdown of PRL‑3 inhibits cell invasion and downregulates ERK 1/2 expression in the human gastric cancer cell line, SGC‑7901.	Today's News Items Roche\'s obinutuzumab (GA101) significantly reduced the risk of disease progression or death in people with one of the most common forms of blood cancer Training Courses & Meetings No events listed Previous News Items FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Supplemental BLA Accepted for Filing by the FDA Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA) For faster discovery, automatically organize PubMed results into categories